user

Pravastatin cost-effectiveness for primary prevention of cardiovascular disease in the US

被引：0
|
作者：
Hay, JW
Yuan, Y
Ford, I
McGuire, A
Shepherd, J
机构：
[1] UNIV GLASGOW,GLASGOW G12 8QQ,LANARK,SCOTLAND
[2] UNIV OXFORD,OXFORD OX1 2JD,ENGLAND
[3] UNIV GLASGOW,GLASGOW,LANARK,SCOTLAND
来源：
CIRCULATION | 1997年 / 96卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1017 / 1017
页数：1
相关论文
共 50 条
  • [21] Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis
    Mieraf Taddesse Tolla
    Ole Frithjof Norheim
    Solomon Tessema Memirie
    Senbeta Guteta Abdisa
    Awel Ababulgu
    Degu Jerene
    Melanie Bertram
    Kirsten Strand
    Stéphane Verguet
    Kjell Arne Johansson
    [J]. Cost Effectiveness and Resource Allocation, 14
  • [22] Cost-effectiveness of cardiovascular disease prevention and management in the developing world
    Alexandra King
    [J]. Nature Reviews Cardiology, 2012, 9 (5) : 258 - 258
  • [23] Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly
    Lin, Liang
    Teng, Monica
    Zhao, Ying Jiao
    Khoo, Ai Leng
    Seet, Raymond Chee Seong
    Yong, Quek Wei
    Yeo, Tiong Cheng
    Lim, Boon Peng
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2015, 29 (02) : 187 - 197
  • [24] Cost-effectiveness of icosapent ethyl for primary and secondary cardiovascular prevention in the UK
    Michaeli, D. T.
    Michaeli, J. C.
    Boch, T.
    Michaeli, T.
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 : 2845 - 2845
  • [25] Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium
    Neyt, Mattias
    De laet, Chris
    Van Brabandt, Hans
    Franco, Oscar
    Ramaekers, Dirk
    [J]. ACTA CARDIOLOGICA, 2009, 64 (01) : 1 - 10
  • [26] Cost-effectiveness modelling of low-dose aspirin for the primary prevention of cardiovascular disease.
    Liew, D
    Vos, T
    Bertram, M
    Lim, S
    McNeil, JJ
    [J]. CIRCULATION, 2004, 109 (07) : E90 - E90
  • [27] Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly
    Liang Lin
    Monica Teng
    Ying Jiao Zhao
    Ai Leng Khoo
    Raymond Chee Seong Seet
    Quek Wei Yong
    Tiong Cheng Yeo
    Boon Peng Lim
    [J]. Cardiovascular Drugs and Therapy, 2015, 29 : 187 - 197
  • [28] COST-EFFECTIVENESS OF STATIN PRIORITISATION BASED ON ABSOLUTE RISK REDUCTION FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE
    Kohli-Lynch, C. N.
    Moran, A. E.
    Thanassoulis, G.
    Sniderman, A. D.
    Zhang, Y.
    Pencina, M.
    Pletcher, M. J.
    Vittinghoff, E.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A614 - A614
  • [29] CARDIOVASCULAR GENETIC RISK TESTING FOR TARGETING STATIN THERAPY IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: A COST-EFFECTIVENESS ANALYSIS
    Jarmul, Jamie A.
    Pletcher, Mark J.
    Earnshaw, Stephanie
    Weinberger, Morris
    Jonas, Daniel
    Avery, Christy
    Lich, Kristen Hassmiller
    Wheeler, Stephanie
    Pignone, Michael
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2017, 32 : S133 - S134
  • [30] Cost-effectiveness of aspirin for the primary prevention of coronary heart disease
    Rodondi, Nicolas
    Moran, Andrew
    Coxson, Pamela G.
    Lightwood, James
    Williams, Lawrence W.
    Cornuz, Jacques
    Goldman, Lee
    [J]. CIRCULATION, 2006, 114 (18) : 827 - 827
12345